more

Abbott Laboratories (ABT)

(Delayed Data from NYSE)

$119.39 USD

+1.50 (1.27%)

Updated Oct 18, 2024 04:00 PM ET

After-Market: $119.40 +0.01 (0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank	Definition	Annualized Return
1	Strong Buy	24.10%
2	Buy	17.80%
3	Hold	9.50%
4	Sell	2.70%
5	Strong Sell	2.70%
S&P	500	11.20%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5 3

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score	A
Growth Score	A
Momentum Score	A
VGM Score	A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value D Growth A Momentum C VGM

Industry Rank:

Top 28% (71 out of 250)

Industry: Medical - Products

View All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Medical Products Industry Outlook: Growth Prospects Bright

by Trina Mukherjee Published on February 28,2020

Growth prospects look bright for the Zacks Medical Products industry, courtesy of AI, Medical Mechatronics and Robotics and growing R&D expenditure.

medical

Genetic Test Gets Okayed by FDA: 4 Stocks to Keep an Eye On

by Sriparna Ghosal Published on February 27,2020

The growth in genetic testing market can be attributed to factors like rise in incidence of genetic disorders, cancer and technological breakthroughs.

medical

Abbott's Alliance With Insulet to Fortify Diabetic Care Unit

by Zacks Equity Research Published on February 24,2020

Both Abbott (ABT) and Insulet will use a pay-as-you-go model to enhance customer acceptance.

medical

Insulet Partners With Dexcom for Automated Insulin Delivery

by Zacks Equity Research Published on February 24,2020

This agreement is a major step forward in Insulet's (PODD) commitment toward bolstering its automated insulin delivery system and providing better clinical outcomes for diabetes patients.

medical

3 Medical Product Stocks Likely to Beat This Earnings Season

by Trina Mukherjee Published on February 13,2020

Despite the ongoing US-China trade war, solid growth in emerging markets is likely to have contributed to the performance of the players in the medical products space this earnings season.

Sonoco (SON) Meets Q4 Earnings Estimates

by Zacks Equity Research Published on February 13,2020

Sonoco (SON) delivered earnings and revenue surprises of 0.00% and 0.35%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

Medical Products Stock Q4 Earnings on Feb 13: DXCM, LH & More

by Urmimala Biswas Published on February 12,2020

Strong foothold in the emerging markets so far widely contributes to some of the industry players' Q4 results.

Medical Products Stock Feb 6 Earnings Roster: BDX, CAH & More

by Zacks Equity Research Published on February 05,2020

Despite the ongoing US-China trade war, increased focus on innovation is likely to have driven performance of medical products players' quarterly performance.

Breaking Q4 Earnings News

by Zacks Equity Research Published on January 22,2020

Breaking Q4 Earnings News

Chicago Econ Numbers & More Q4 Earnings: JNJ, ABT, FITB

by Mark Vickery Published on January 22,2020

Certain weeks of the year are rife with important information for the stock market. This is not one of those weeks.

industrial-products

Abbott (ABT) Q4 Earnings Match Estimates, Revenues Beat Mark

by Zacks Equity Research Published on January 22,2020

We are upbeat about Abbott's (ABT) strong and consistent EPD and Medical Devices performances, organically.

Abbott (ABT) Meets Q4 Earnings Estimates

by Zacks Equity Research Published on January 22,2020

Abbott (ABT) delivered earnings and revenue surprises of 0.00% and 0.63%, respectively, for the quarter ended December 2019. Do the numbers hold clues to what lies ahead for the stock?

ABTPositive Net Change

Can Abbott (ABT) Q4 Earnings Ride on Growth in All Lines?

by Zacks Equity Research Published on January 20,2020

Abbott's (ABT) imminent quarterly results are expected to reflect a solid performance by the Established Pharmaceuticals Division (EPD) business alike the last reported quarter.

Diabetes Management Gains FDA Attention: 3 Stocks in Focus

by Sriparna Ghosal Published on January 17,2020

The FDA recently authorized diabetes care companies to start pairing their medical devices for diabetes management, by combining insulin pumps and glucose monitors.

medical

3 Medical Product Stocks Set to Beat This Earnings Season

by Urmimala Biswas Published on January 16,2020

Here we discuss three medical product stocks that are due to report soon and are likely to beat estimates on earnings, riding on a host of factors.

Abbott (ABT) Reports Next Week: Wall Street Expects Earnings Growth

by Zacks Equity Research Published on January 15,2020

Abbott (ABT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

ABTPositive Net Change

7 Dividend ETFs That Offer Growth in 2020

by Sweta Killa Published on January 14,2020

In a low interest rate environment, dividend investing has been the hot spot and seems an excellent choice for 2020.

etfs

Abbott's Less-Invasive Surgery for Heart Pump Gets FDA Nod

by Zacks Equity Research Published on January 08,2020

Abbott's (ABT) less invasive approach for heart surgery for its heart pump gets the FDA clearance, thus paving the way for avoiding open heart surgeries.